Pinealon (also known as EDR) is a synthetic tripeptide (Glu-Asp-Arg) developed in Russia. In preclinical and in vitro research, it is studied for its neuroprotective effects and its potential to interact with DNA to modulate gene expression. It is not FDA-approved for human use.

Key Details & Research

• Amino Acid Sequence: Glutamic Acid, Aspartic Acid, and Arginine.

• Proposed Mechanisms: Research focuses on its ability to cross the blood-brain barrier, promote neuronal survival by reducing apoptosis (programmed cell death), and support circadian rhythm regulation.

• Target Audience: The peptide is primarily discussed in longevity and biohacking circles for cognitive support and sleep optimization.

  
  

Current Evidence

• Human Trials: There are no completed, large-scale randomized controlled trials (RCTs) backing its efficacy in humans. The vast majority of peer-reviewed studies to date are limited to rodent models and in vitro (cell culture) research.

• Regulatory Status: Pinealon is not an FDA-approved drug and does not have a regulatory classification as a bulk drug substance for compounding. In the United States, it is largely restricted to controlled laboratory or research-only environments.

For more information on the preclinical research and pharmacology of EDR, you can review the systematic study on ⁠NCBI.

This is for informational purposes only. For medical advice or diagnosis, consult a professional.

This product for research use only.